Full Press Release Details
ADVISORY, July 26, 2012 (GLOBE NEWSWIRE) --
OraSure Technologies, Inc. [OSUR], leaders in the development, manufacture and distribution of technologies used to detect or diagnose critical medical conditions, including HCV and HIV, will visit the NASDAQ MarketSite in Times Square on July 27th in honor of World Hepatitis Day.
OraSure Technologies' OraQuick HCV Rapid Antibody Test is the only FDA approved rapid hepatitis C test in the U.S. It is used in the U.S. and around the would to diagnose people at risk for hepatitis C, a disease that affects over 4 million people in the U.S., and nearly 180 million people globally.
OraSure also recently received U.S. Food and Drug Administration (FDA) approval for the Company's OraQuick In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market - making it the first and only rapid OTC HIV test approved in the U.S.
To mark the occasion Douglas Michels, OraSure President & CEO will ring the Closing Bell.
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio
Friday, July 27, 2012 - 3:45 p.m. to 4:00 p.m. ET
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About OraSure Technologies, Inc. [OSUR]:
OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.